DrugPatentWatch Database Preview

Eli Lilly And Co Company Profile

« Back to Dashboard

What is the competitive landscape for ELI LILLY AND CO, and when can generic versions of ELI LILLY AND CO drugs launch?

ELI LILLY AND CO has six approved drugs.

There are thirteen US patents protecting ELI LILLY AND CO drugs.

There are one hundred and seventy-three patent family members on ELI LILLY AND CO drugs in forty-nine countries and fifty-one supplementary protection certificates in twelve countries.

Summary for Eli Lilly And Co

International Patents:	173
US Patents:	13
Tradenames:	7
Ingredients:	6
NDAs:	6
Drug Master File Entries:	36

Drugs and US Patents for Eli Lilly And Co

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eli Lilly And Co	VERZENIO	abemaciclib	TABLET;ORAL	208716-002	Sep 28, 2017		RX	Yes	No	7,855,211		Y	Y
Eli Lilly And Co	EFFIENT	prasugrel hydrochloride	TABLET;ORAL	022307-002	Jul 10, 2009	AB	RX	Yes	Yes	8,404,703*PED				Y
Eli Lilly And Co	HUMALOG KWIKPEN	insulin lispro recombinant	SOLUTION;SUBCUTANEOUS	205747-001	May 26, 2015		RX	Yes	Yes	6,551,992		Y
Eli Lilly And Co	HUMALOG KWIKPEN	insulin lispro recombinant	SOLUTION;SUBCUTANEOUS	205747-001	May 26, 2015		RX	Yes	Yes	6,034,054		Y

Expired US Patents for Eli Lilly And Co

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Eli Lilly And Co	PROZAC	fluoxetine hydrochloride	CAPSULE;ORAL	018936-006	Dec 23, 1992	4,314,081*PED
Eli Lilly And Co	PROZAC	fluoxetine hydrochloride	CAPSULE;ORAL	018936-006	Dec 23, 1992	4,626,549*PED
Eli Lilly And Co	PROZAC	fluoxetine hydrochloride	CAPSULE;ORAL	018936-003	Jun 15, 1999	4,314,081*PED
Eli Lilly And Co	PROZAC	fluoxetine hydrochloride	CAPSULE;ORAL	018936-006	Dec 23, 1992	6,960,577

Paragraph IV (Patent) Challenges for ELI LILLY AND CO drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Topical Solution	30 mg/1.5 mL		2013-01-29
	Tablets	5 mg and 10 mg		2013-07-10

Non-Orange Book US Patents for Eli Lilly And Co

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
7,427,275	Medication dispensing apparatus with triple screw threads for mechanical advantage
8,177,449	Spreading implement
8,357,393	Transdermal delivery rate control using amorphous pharmaceutical compositions
6,906,028	Stable insulin formulations

International Patents for Eli Lilly And Co Drugs

Country	Document Number	Estimated Expiration
Eurasian Patent Organization	200500084
Israel	133348
Hong Kong	1077192
Argentina	074575

Supplementary Protection Certificates for Eli Lilly And Co Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C0020	France		PRODUCT NAME: INSULIN DETEMIR; NAT. REGISTRATION NO/DATE: EU/1/04/278/001 20040601; FIRST REGISTRATION: LI - 56370 20031110
213	Luxembourg		PRODUCT NAME: INSULINE DEGLUDEC SOUS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE
2209800/01	Switzerland		PRODUCT NAME: INSULIN DEGLUDEC + LIRAGLUTIDE; REGISTRATION NO/DATE: SWISSMEDIC 65041 12.09.2014
C/GB09/032	United Kingdom		PRODUCT NAME: PRASUGREL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/08/503/001 20090225; UK EU/1/08/503/002 20090225; UK EU/1/08/503/003 20090225; UK EU/1/08/503/004 20090225

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Eli Lilly And Co
• Eli Lilly Co